Another step toward new drugs for Parkinson’s

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, everyone. Damian here with the plight of the venture capitalist, an idea for Gilead Sciences, and the latest in the quest to find potent treatments for Parkinson’s disease.

The need-to-know this morning

• Cancer drug developer CG Oncology raised $380 million in an initial public offering. It’s the first biotech IPO of 2024.

Biotech VCs are feeling the squeeze

As fledgling drug companies struggle to raise the cash they need to survive, spare a moment for the venture capitalists on the other side of the Zoom screen.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In